Cargando…

COVID‐19 diagnostic testing: Technology perspective

The corona virus disease 2019 (COVID‐19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). More than 18 million people were infected with a total of 0.7 million deaths in ∼188 countries. Controlling the spread of SARS‐CoV‐2 is therefore inhere...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Meng, Wang, Dan, Wang, Hongye, Zhang, Xiaomei, Liang, Te, Dai, Jiayu, Li, Meng, Zhang, Jiahui, Zhang, Kai, Xu, Danke, Yu, Xiaobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443140/
https://www.ncbi.nlm.nih.gov/pubmed/32898340
http://dx.doi.org/10.1002/ctm2.158
_version_ 1783573576158281728
author Xu, Meng
Wang, Dan
Wang, Hongye
Zhang, Xiaomei
Liang, Te
Dai, Jiayu
Li, Meng
Zhang, Jiahui
Zhang, Kai
Xu, Danke
Yu, Xiaobo
author_facet Xu, Meng
Wang, Dan
Wang, Hongye
Zhang, Xiaomei
Liang, Te
Dai, Jiayu
Li, Meng
Zhang, Jiahui
Zhang, Kai
Xu, Danke
Yu, Xiaobo
author_sort Xu, Meng
collection PubMed
description The corona virus disease 2019 (COVID‐19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). More than 18 million people were infected with a total of 0.7 million deaths in ∼188 countries. Controlling the spread of SARS‐CoV‐2 is therefore inherently dependent on identifying and isolating infected individuals, especially since COVID‐19 can result in little to no symptoms. Here, we provide a comprehensive review of the different primary technologies used to test for COVID‐19 infection, discuss the advantages and disadvantages of each technology, and highlight the studies that have employed them. We also describe technologies that have the potential to accelerate SARS‐CoV‐2 detection in the future, including digital PCR, CRISPR, and microarray. Finally, remaining challenges in COVID‐19 diagnostic testing are discussed, including (a) the lack of universal standards for diagnostic testing; (b) the identification of appropriate sample collection site(s); (c) the difficulty in performing large population screening; and (d) the limited understanding of SARS‐COV‐2 viral invasion, replication, and transmission.
format Online
Article
Text
id pubmed-7443140
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74431402020-08-28 COVID‐19 diagnostic testing: Technology perspective Xu, Meng Wang, Dan Wang, Hongye Zhang, Xiaomei Liang, Te Dai, Jiayu Li, Meng Zhang, Jiahui Zhang, Kai Xu, Danke Yu, Xiaobo Clin Transl Med Reviews The corona virus disease 2019 (COVID‐19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). More than 18 million people were infected with a total of 0.7 million deaths in ∼188 countries. Controlling the spread of SARS‐CoV‐2 is therefore inherently dependent on identifying and isolating infected individuals, especially since COVID‐19 can result in little to no symptoms. Here, we provide a comprehensive review of the different primary technologies used to test for COVID‐19 infection, discuss the advantages and disadvantages of each technology, and highlight the studies that have employed them. We also describe technologies that have the potential to accelerate SARS‐CoV‐2 detection in the future, including digital PCR, CRISPR, and microarray. Finally, remaining challenges in COVID‐19 diagnostic testing are discussed, including (a) the lack of universal standards for diagnostic testing; (b) the identification of appropriate sample collection site(s); (c) the difficulty in performing large population screening; and (d) the limited understanding of SARS‐COV‐2 viral invasion, replication, and transmission. John Wiley and Sons Inc. 2020-08-22 /pmc/articles/PMC7443140/ /pubmed/32898340 http://dx.doi.org/10.1002/ctm2.158 Text en © 2020 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Xu, Meng
Wang, Dan
Wang, Hongye
Zhang, Xiaomei
Liang, Te
Dai, Jiayu
Li, Meng
Zhang, Jiahui
Zhang, Kai
Xu, Danke
Yu, Xiaobo
COVID‐19 diagnostic testing: Technology perspective
title COVID‐19 diagnostic testing: Technology perspective
title_full COVID‐19 diagnostic testing: Technology perspective
title_fullStr COVID‐19 diagnostic testing: Technology perspective
title_full_unstemmed COVID‐19 diagnostic testing: Technology perspective
title_short COVID‐19 diagnostic testing: Technology perspective
title_sort covid‐19 diagnostic testing: technology perspective
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443140/
https://www.ncbi.nlm.nih.gov/pubmed/32898340
http://dx.doi.org/10.1002/ctm2.158
work_keys_str_mv AT xumeng covid19diagnostictestingtechnologyperspective
AT wangdan covid19diagnostictestingtechnologyperspective
AT wanghongye covid19diagnostictestingtechnologyperspective
AT zhangxiaomei covid19diagnostictestingtechnologyperspective
AT liangte covid19diagnostictestingtechnologyperspective
AT daijiayu covid19diagnostictestingtechnologyperspective
AT limeng covid19diagnostictestingtechnologyperspective
AT zhangjiahui covid19diagnostictestingtechnologyperspective
AT zhangkai covid19diagnostictestingtechnologyperspective
AT xudanke covid19diagnostictestingtechnologyperspective
AT yuxiaobo covid19diagnostictestingtechnologyperspective